Psychodiabetologie – Hellmut-Otto-Medaille 2019 – eine Kurzübersicht der Preisträger Bernhard Kulzer und Norbert Hermanns

Bernhard Kulzer; Norbert Hermanns

doi:10.1055/a-0947-2833

Diabetologie und Stoffwechsel, Table of Contents

Diabetologie und Stoffwechsel 2019; 14(05): 359-361
DOI: 10.1055/a-0947-2833

DDG-Preisträger

Psychodiabetologie – Hellmut-Otto-Medaille 2019 – eine Kurzübersicht der Preisträger Bernhard Kulzer und Norbert Hermanns

Bernhard Kulzer

Forschungsinstitut der Diabetes-Akademie Bad Mergentheim (FIDAM)

,

Norbert Hermanns

Forschungsinstitut der Diabetes-Akademie Bad Mergentheim (FIDAM)

› Author Affiliations

Abstract

Full Text

References

Literatur
1 Kulzer B, Hermanns N. Diabetes als verhaltensmedizinische Erkrankung. In: Häring HU, Galwitz B, Müller-Wieland D. et al. (Hrsg) Diabetologie in Klinik und Praxis. 6.. Aufl. Stuttgart: Thieme-Verlag; 2011: 268-282
2 Kulzer B, Hermanns N, Reinecker H. et al. Effects of self-management training in Type 2 diabetes: a randomized, prospective trial. Diabetic Medicine 2007; 24 (04) 415-423
3 Hermanns N, Kulzer B, Maier B. et al. The effect of an education programme (MEDIAS 2 ICT) involving intensive insulin treatment for people with type 2 diabetes. Patient Education and Counseling 2012; 86 (02) 226-232
4 Hermanns N, Ehrmann D, Schall S. et al. The effect of an education programme (MEDIAS 2 BSC) of non-intensive insulin treatment regimens for people with Type 2 diabetes: a randomized, multi-centre trial. Diabetic Medicine 2017; 34 (08) 1084-1091
5 Hermanns N, Kulzer B, Ehrmann D. et al. The effect of a diabetes education programme (PRIMAS) for people with type 1 diabetes: results of a randomized trial. Diabetes Research and Clinical Practice 2013; 102 (03) 149-157
6 Ehrmann D, Bergis-Jurgan N, Haak T. et al. Comparison of the efficacy of a diabetes education programme for type 1 diabetes (PRIMAS) in a randomised controlled trial setting and the effectiveness in a routine care setting: Results of a comparative effectiveness study. PLoS One 2016; 11 (01) e0147581
7 Ehrmann D, Kulzer B, Schipfer M. et al. Efficacy of an education program for people with diabetes and insulin pump ireatment (INPUT): Results from a randomized controlled trial. Diabetes Care 2018; 41 (12) 2453-2462
8 Bergis D, Ehrmann D, Albrecht C. et al. Comparison of the efficacy of an education program for people with diabetes and insulin pump treatment (INPUT) in a randomized controlled trial setting and the effectiveness in a routine care setting: Results of a comparative effectiveness study. Patient Education and Counseling 2019; 102 (10) 1868-1874
9 Hermanns N, Ehrmann D, Schipfer M. et al. The impact of a structured education and treatment programme (FLASH) for people with diabetes using a flash sensor-based glucose monitoring system: Results of a randomized controlled trial. Diabetes Research and Clinical Practice 2019; 150: 111-121
10 Hermanns N, Kulzer B, Kubiak T. et al. The effect of an education programme (HyPOS) to treat hypoglycaemia problems in patients with type 1 diabetes. Diabetes Metabolism Research and Reviews 2007; 23 (07) 528-538
11 Hermanns N, Kulzer B, Krichbaum M. et al. Long-term effect of an education program (HyPOS) on the incidence of severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 2010; 33 (03) e36
12 Kulzer B, Hermanns N, Gorges D. et al. Prevention of diabetes self-management program (PREDIAS): effects on weight, metabolic risk factors, and behavioral outcomes. Diabetes Care 2009; 32 (07) 1143-1146
13 Peyrot M, Burns KK, Davies M. et al. Diabetes Attitudes Wishes and Needs 2 (DAWN2): a multinational, multi-stakeholder study of psychosocial issues in diabetes and person-centred diabetes care. Diabetes Research and Clinical Practice 2013; 99 (02) 174-184
14 Nicolucci A, Kovacs Burns K, Holt RI. et al. Diabetes Attitudes, Wishes and Needs second study (DAWN2™): cross-national benchmarking of diabetes-related psychosocial outcomes for people with diabetes. Diabetic Medicine 2013; 30 (07) 767-777
15 Kovacs Burns K, Nicolucci A, Holt RI. et al. Diabetes Attitudes, Wishes and Needs second study (DAWN2™): cross-national benchmarking indicators for family members living with people with diabetes. Diabetic Medicine 2013; 30 (07) 778-788
16 Holt RI, Nicolucci A, Kovacs Burns K. et al. Diabetes Attitudes, Wishes and Needs second study (DAWN2™): cross-national comparisons on barriers and resources for optimal care--healthcare professional perspective. Diabetic Medicine 2013; 30 (07) 789-798
17 Kulzer B, Lüthgens B, Landgraf R. et al. Diabetesbezogene Belastungen, Wohlbefinden und Einstellung von Menschen mit Diabetes – Deutsche Ergebnisse der DAWN2™-Studie. Diabetologe 2015; 11 (03) 211-218
18 Kulzer B, Lüthgens B, Landgraf R. et al. Wie belastend erleben Angehörige den Diabetes? Deutsche Stichprobe der internationalen DAWN2™-Studie. Diabetologe 2017; 13 (08) 570-580
19 Hermanns N, Schmitt A, Gahr A. et al. The effect of a Diabetes-Specific Cognitive Behavioral Treatment Program (DIAMOS) for patients with diabetes and subclinical depression: results of a randomized controlled trial. Diabetes Care 2015; 38 (04) 551-560
20 Herder C, Hermanns N. Subclinical inflammation and depressive symptoms in patients with type 1 and type 2 diabetes. Semin Immunopathol 2019; 41 (04) 477-489
21 Herder C, Schmitt A, Budden F. et al. Association between pro- and anti-inflammatory cytokines and depressive symptoms in patients with diabetes-potential differences by diabetes type and depression scores. Transl Psychiatry 2018; 7 (11) 1
22 Herder C, Schmitt A, Budden F. et al. Longitudinal associations between biomarkers of inflammation and changes in depressive symptoms in patients with type 1 and type 2 diabetes. Psychoneuroendocrinology 2018; 91: 216-225
23 Heinemann L, Freckmann G, Ehrmann D. et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet 2018; 391: 1367-1377
24 Hermanns N, Heinemann L, Freckmann G. et al. Impact of CGM on the management of hypoglycemia problems: Overview and secondary analysis of the HypoDE study. J Diabetes Sci Technol 2019; 13 (04) 636-644
25 Davies MJ, D'Alessio DA, Fradkin J. et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41 (12) 2669-2701 . | Diabetologia 61(12): 2461–2498
26 Kulzer B, Daenschel W, Daenschel I. et al. Integrated Personalized Diabetes Management (PDM): Design of the ProValue studies. J Diabetes Sci Technol 2016; 10 (03) 772-781
27 Kulzer B, Daenschel W, Daenschel I. et al. Integrated personalized diabetes management improves glycemic control in patients with insulin-treated type 2 diabetes: Results of the PDM-ProValue study program. Diabetes Research and Clinical Practice 2018; 144: 200-212
28 Heinemann L, Schramm W, Koenig H. et al. Benefit of digital tools used for integrated personalized diabetes management: Results from the PDM-ProValue study program. J Diabetes Sci Technol. 2019 Aug 5:1932296819867686. [Epub ahead of print]
29 Heinemann L, Kulzer B. (Hrsg) Digitalisierungs- und Technologie-Report Diabetes. Mainz: Kirchheim-Verlag; 2019
30 Kulzer B, Albus C, Herpertz S. et al. Psychosoziales und Diabetes (Teil 1). S2-Leitlinie Psychosoziales und Diabetes – Langfassung. Diabetologie und Stoffwechsel 2013; 8 (03) 198-242
31 Kulzer B, Albus C, Herpertz S. et al. Psychosoziales und Diabetes (Teil 1). S2-Leitlinie Psychosoziales und Diabetes – Langfassung. Diabetologie und Stoffwechsel 2013; 8 (04) 292-324